{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:35:25Z","timestamp":1794591325553,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["(RSP2024R77)"],"award-info":[{"award-number":["(RSP2024R77)"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10763-3","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T09:03:48Z","timestamp":1742288628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence and predictors of vancomycin nephrotoxicity and mortality in patients with chronic liver disease: a two-center retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Reem F.","family":"Bamogaddam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha","family":"Alqarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Almotairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Almakrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwaleed M.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Altamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Alkhulaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed S.","family":"Al Yami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"Suppl 1","key":"10763_CR1","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.nephro.2018.02.009","volume":"14","author":"Y Luque","year":"2018","unstructured":"Luque Y, Mesnard L. Vancomycin nephrotoxicity: frequency and mechanistic aspects. Nephrol Ther. 2018;14(Suppl 1):S133\u20138. https:\/\/doi.org\/10.1016\/j.nephro.2018.02.009.","journal-title":"Nephrol Ther"},{"issue":"1","key":"10763_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5005\/jp-journals-10081-1387","volume":"5","author":"B Shenoy","year":"2023","unstructured":"Shenoy B, Joshi DN, Doddikoppad P. Vancomycin therapeutic drug monitoring. Pediatr Infect Dis. 2023;5(1):17\u20139. https:\/\/doi.org\/10.5005\/jp-journals-10081-1387.","journal-title":"Pediatr Infect Dis"},{"issue":"2","key":"10763_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734\u201344. https:\/\/doi.org\/10.1128\/AAC.01568-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10763_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036.","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"10763_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361. https:\/\/doi.org\/10.1007\/s00228-008-0553-z.","journal-title":"Eur J Clin Pharmacol"},{"key":"10763_CR6","doi-asserted-by":"publisher","unstructured":"Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg M, et al. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open. 2016;6(10):e012991. https:\/\/doi.org\/10.1136\/bmjopen-2016-012991.","DOI":"10.1136\/bmjopen-2016-012991"},{"issue":"2","key":"10763_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/0018578718772266","volume":"54","author":"RE Regal","year":"2019","unstructured":"Regal RE, Ren SP, Paige G, Alaniz C. Evaluation of vancomycin dosing in patients with cirrhosis: beginning de-liver-ations about a new nomogram. Hosp Pharm. 2019;54(2):125\u20139. https:\/\/doi.org\/10.1177\/0018578718772266.","journal-title":"Hosp Pharm"},{"key":"10763_CR8","unstructured":"Bauer LA. Applied Clinical Pharmacokinetics. Second edi. New York, USA: McGraw-Hill Professional Publishing; 2008."},{"key":"10763_CR9","unstructured":"Sharma A, Nagalli S. Chronic Liver Disease. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554597\/."},{"issue":"2","key":"10763_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/gastro\/gox009","volume":"5","author":"T Bucsics","year":"2017","unstructured":"Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5(2):127\u201337. https:\/\/doi.org\/10.1093\/gastro\/gox009.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"4","key":"10763_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/AAC.23.4.603","volume":"23","author":"N Brown","year":"1983","unstructured":"Brown N, Ho DHW, Fong KLL, Bogerd L, Maksymiuk A, Bolivar R, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother. 1983;23(4):603\u20139. https:\/\/doi.org\/10.1128\/AAC.23.4.603.","journal-title":"Antimicrob Agents Chemother"},{"key":"10763_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/CIA.S52259","volume":"8","author":"T Mizuno","year":"2013","unstructured":"Mizuno T, Mizokami F, Fukami K, Ito K, Shibasaki M, Nagamatsu T, Furuta K. The influence of severe hypoalbuminemia on the half-life of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging. 2013;8:1323\u20138. https:\/\/doi.org\/10.2147\/CIA.S52259.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"10763_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12941-020-00354-2","volume":"19","author":"L Brunetti","year":"2020","unstructured":"Brunetti L, Song JH, Suh D, Kim HJ, Seong YH, Lee DS, Lee SM, Suh DC. The risk of vancomycin toxicity in patients with liver impairment. Ann Clin Microbiol Antimicrob. 2020;19(1):13. https:\/\/doi.org\/10.1186\/s12941-020-00354-2.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"10763_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/00007691-200006000-00004","volume":"22","author":"A Aldaz","year":"2000","unstructured":"Aldaz A, Ortega A, Idoate A, Gir\u00e1ldez J, Brugarolas A. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit. 2000;22(3):250\u20137. https:\/\/doi.org\/10.1097\/00007691-200006000-00004.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10763_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s101560050018","volume":"5","author":"H Harada","year":"1999","unstructured":"Harada H, Miyagawa S, Kawasaki S, Hayashi K, Kitamura H, Katsuyama Y, Atobe O, Tada A, Zenda H, Oguma T. Study of the pharmacokinetics of vancomycin in patients with impaired liver function. J Infect Chemother. 1999;5(2):104\u20137. https:\/\/doi.org\/10.1007\/s101560050018.","journal-title":"J Infect Chemother"},{"issue":"2","key":"10763_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1600-0773.1996.tb00242.x","volume":"79","author":"R Mart\u00ed","year":"1996","unstructured":"Mart\u00ed R, Rosell M, Pou L, Garc\u00eda L, Pascual C. Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. Pharmacol Toxicol. 1996;79(2):55\u20139. https:\/\/doi.org\/10.1111\/j.1600-0773.1996.tb00242.x.","journal-title":"Pharmacol Toxicol"},{"key":"10763_CR17","unstructured":"Vancocin Powder for Solution. Summary of Product Characteristics. Medicines.org.uk; [cited 2025 Feb 6]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/6407\/smpc."},{"issue":"5","key":"10763_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"10763_CR19","unstructured":"KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Disease: Improving Global Outcomes (KDIGO); [cited 2025 Feb 6]. Available from: https:\/\/kdigo.org\/guidelines\/acute-kidney-injury\/."},{"issue":"18","key":"10763_CR20","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1002\/sim.10133","volume":"43","author":"MD Rohde","year":"2024","unstructured":"Rohde MD, French B, Stewart TG, Harrell FE. Bayesian transition models for ordinal longitudinal outcomes. Stat Med. 2024;43(18):3539\u201361. https:\/\/doi.org\/10.1002\/sim.10133.","journal-title":"Stat Med"},{"key":"10763_CR21","unstructured":"Harrell F. Bayesian Regression Modeling Strategies [R package rmsb version 1.1-1]. 2024 [cited 2025 Feb 6]. Available from: https:\/\/cran.r-project.org\/web\/packages\/rmsb\/index.html."},{"issue":"13","key":"10763_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMra0809139","volume":"361","author":"P Gin\u00e8s","year":"2009","unstructured":"Gin\u00e8s P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279\u201390. https:\/\/doi.org\/10.1056\/NEJMra0809139.","journal-title":"N Engl J Med"},{"issue":"2","key":"10763_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/003655102753611753","volume":"62","author":"E Randers","year":"2002","unstructured":"Randers E, Ivarsen P, Erlandsen EJ, Hansen EF, Aagaard NK, Bendtsen F, Vilstrup H. Plasma cystatin C as a marker of renal function in patients with liver cirrhosis. Scand J Clin Lab Invest. 2002;62(2):129\u201334. https:\/\/doi.org\/10.1080\/003655102753611753.","journal-title":"Scand J Clin Lab Invest"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10763-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10763-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10763-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T09:03:51Z","timestamp":1742288631000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10763-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10763"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10763-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out according to the principles of the Declaration of Helsinki, and approval was granted by the Institutional Review Boards at KAMC (IRB: 1755\/23) and KFMC (IRB: 24\u2013015). Due to the retrospective nature of the study, the need to obtain informed consent was waived by Institutional Review Boards at KAMC (IRB: 1755\/23) and KFMC (IRB: 24\u2013015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"375"}}